Clinical trial
A Phase 2 Study to Evaluate Safety, Tolerability, And Virologic Efficacy of ARN-75039 For the Treatment of Lassa Fever in West Africa
NCT07419373 is registered in ClinicalTrials.gov with Arisan Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study to Evaluate Safety, Tolerability, And Virologic Efficacy of ARN-75039 For the Treatment of Lassa Fever in West Africa
- Lead sponsor
- Arisan Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- February 14, 2026
- Completion date
- June 30, 2027
- Enrollment
- 135 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.